Internal Med Medical News about Diabetes Mellitus Diabetes Mellitus, Type 2

Your Unread Messages

See All

Tracy Hampton, PhD

Conference Flash

Leukemia-Associated Protein Has Effects in Breast Tissue

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Circulating Breast Cancer Cells Validated as Index of Metastases

Sara Hartley

Cancer Science

Low Sugar Environment Promotes Oncogenic Mutations

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies
Diabetes, Obesity and Metabolism, 11/06/09

Blonde L et al. – Liraglutide is a new glucagon–like peptide–1 (GLP–1) receptor agonist and a true GLP–1 analogue. After successful phase 2 studies, liraglutide was assessed in a series of phase 3 trials. Liraglutide was associated with a low risk of hypoglycaemia and was generally well tolerated. The majority of adverse effects were gastrointestinal, the most frequent of which was nausea.

<< Previous
Impact of Low Glucose Degradation Product...

Next >>
The phenotypic profile of dermatomyositis and lupus...